Compare LXEO & ALOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LXEO | ALOV |
|---|---|---|
| Founded | 2017 | 2025 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.7M | 374.4M |
| IPO Year | 2023 | 2025 |
| Metric | LXEO | ALOV |
|---|---|---|
| Price | $4.28 | $9.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $18.44 | N/A |
| AVG Volume (30 Days) | ★ 679.5K | 109.9K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.99 | $9.83 |
| 52 Week High | $10.99 | $10.00 |
| Indicator | LXEO | ALOV |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 54.40 |
| Support Level | $4.01 | N/A |
| Resistance Level | $5.38 | N/A |
| Average True Range (ATR) | 0.24 | 0.01 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 5.59 | 60.00 |
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Aldabra 4 Liquidity Opportunity Vehicle Inc is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.